Reasons to participate in clinical research
While it may seem scary to participate in research, there are many ways that research scientists, study doctors, the FDA and third party ethics committees help keep volunteers safe. Close monitoring of your well-being and study-related care by study and other healthcare professionals also help ensure your safety. Additionally you will be fully informed of the potential risks and benefits of participating so you can feel comfortable with your decision to volunteer. Also you can always choose to stop participating at any time for any reason.
Institutional review board (IRBs), the FDA and the office of Human Subjects research Protection are all agencies that monitor a study's ethic, safety and the participant's rights.
Here are some reasons to consider volunteering for a clinical trial with us:
- Receive thorough and frequent care from medical professionals at no cost. No insurance is needed.
- Learn more about your health and medical conditions, and take a more active role in your own medical decisions and treatments.
- Potentially gain access to new treatments before the general public.
- In many cases, receive compensation for time and travel while participating in the study.
- Help the medical community learn more about potential treatments to detect, prevent and treat common diseases and conditions.
Current Studies
This is an observational study with no intervention.
This is a phase 3 Acute Coronary syndrome infusion study.
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Modified RNA
Vaccines Against Influenza
Evaluation of the efficacy and safety of a Pre-Fusion based RSV vaccine
in ≥60-year-old healthy individuals, compared to Placebo
This is a double-blinded randomized controlled study assessing the effectiveness of isometric handgrip therapy.
Optimizing Beta Blocker Dosage in Women While Using the Wearable Cardioverter Defibrillator
An Open-Label, Randomized, Multicenter Study to Evaluate the
Safety, Efficacy, Pharmacokinetics and Physician Satisfaction of Two
Different Doses of IP
Solution When Used as an Aid in the Determination of
Ureteral Patency.
A Randomized, Double-Blind, Double Dummy, Parallel Group, Multicenter 24 to 52 week Variable Length Study to Assess the Efficacy and Safety of IP in Adult and Adolescent Participants with Inadequately Controlled Asthma
A Phase 2, Randomized, Double-blind, Placebo-controlled Cross-over Study of XXX in Patients with
Parkinson’s Disease Who Are Experiencing Excessive Daytime Sleepiness
A Phase IIb, Randomised, Double Blind, Placebo Controlled, Parallel Group,
Multicentre Dose Ranging Subcutaneous Study of an Anti-OX40L Monoclonal
Antibody (KY1005) in Moderate to Severe Atopic Dermatitis
Non-technical title: A Subcutaneous Dose Ranging Study of KY1005 in Patients
with Moderate to Severe Atopic Dermatitis
Randomized, double-blind, parallel, three-arm, vehicle-controlled in
vivo study in male and nonpregnant female adults with generalized,
moderate-to-advanced periodontitis
APOL1 inhibitor in individuals with APOL1 mediated proteinuric kidney disease
To access the efficacy and safety of BW-20805 in Adults with Hereditary Angioedema
